Insurance Denied MS Treatment? How to Appeal Disease-Modifying Therapy Denials for Ocrevus and Kesimpta

Multiple sclerosis (MS) is a chronic, often disabling disease of the central nervous system affecting approximately 1 million Americans. Disease-modifying therapies (DMTs) are the cornerstone of MS management — reducing relapse rates, slowing disability progression, and in many cases altering the long-term course of the disease. Yet insurers routinely deny access to high-efficacy DMTs like Ocrevus (ocrelizumab) and Kesimpta (ofatumumab), forcing patients through step therapy that allows disease to progress during the trial period.

Why Insurers Deny MS DMTs

• Step therapy from lower-efficacy to higher-efficacy DMTs: Insurers require failure of platform therapies (interferon betas, glatiramer acetate) before approving high-efficacy therapies, contradicting emerging neurological consensus favoring early high-efficacy treatment for high-risk patients
• "Not medically necessary" for the specific MS subtype: Insurer argues the patient's disease is not "active enough" to justify escalation
• Ocrevus denied for primary progressive MS: Despite being the only FDA-approved therapy for PPMS (approved 2017), some insurers create their own criteria beyond the FDA label
• Preferred DMT substitution: Formularies favor older, lower-efficacy interferons over high-efficacy therapies on cost grounds
• Infusion center coverage disputes: Network disputes over infusion centers result in unexpected denials

Common denial codes: CO-50 (not medically necessary), CO-96 (non-covered service), B15 (authorization required), CO-4 (service inconsistency).

How to Appeal an MS DMT Denial

Step 1: Document MS Subtype and Disease Activity

Neurologist notes should include ICD-10 G35 (Multiple sclerosis), MS subtype (RRMS, SPMS, PPMS), EDSS score and functional system scores, relapse history in the past 12–24 months, MRI results (new lesions, gadolinium-enhancing lesions, lesion burden change), and current and prior DMT history with outcomes.

Step 2: Invoke NMSS and AAN Clinical Guidelines

The National Multiple Sclerosis Society (NMSS) Clinical Practice Guidelines support shared decision-making in DMT selection and explicitly endorse early initiation of high-efficacy therapy for appropriate patients — without mandating sequential step therapy. The American Academy of Neurology (AAN) 2018 guideline similarly recommends DMT initiation as early as possible, recognizing that for high-risk patients, high-efficacy therapy may be clinically preferable as first-line treatment. Cite both guidelines directly in your appeal.

Step 3: Challenge Step Therapy in PPMS

For primary progressive MS, Ocrevus is the only FDA-approved therapy. There is no step therapy alternative to fail first — deny this ground directly, citing the FDA approval date (March 2017) and the absence of any alternative approved treatment for PPMS.

Step 4: Use EDSS and MRI Evidence to Establish Treatment Failure

The Expanded Disability Status Scale (EDSS) provides objective disability documentation. An increase in EDSS score over 6–12 months despite DMT therapy demonstrates treatment failure supporting escalation. New T2 lesions or contrast-enhancing lesions on MRI demonstrate radiographic disease activity supporting high-efficacy therapy, even without clinical relapses.

Step 5: Request Peer-to-Peer Review

Ask that the insurer's reviewing physician speak directly with the prescribing MS neurologist. Non-specialist reviewers frequently reverse course after MS-specialist peer-to-peer consultation, given the complexity of DMT selection.

Step 6: File for External Independent Review: Complete Guide" class="auto-link">External Review

MS is a well-studied disease with consensus guidelines. External reviewers with neurology expertise frequently overturn DMT denials that conflict with NMSS or AAN standards.

What to Include in Your Appeal

• Neurologist notes with EDSS scores, relapse history, and MRI reports documenting disease activity
• NMSS and AAN guideline citations supporting the prescribed DMT for the patient's clinical situation
• FDA approval documentation for the specific DMT (especially for PPMS and Ocrevus)
• Prior DMT history with efficacy and tolerability outcomes demonstrating treatment failure
• JC virus antibody status if relevant to natalizumab risk stratification

Fight Back With ClaimBack

MS progression is irreversible — every delay in effective treatment matters. When DMT denials conflict with NMSS guidelines and documented disease activity, they are frequently overturned on appeal. ClaimBack generates a professional appeal letter in 3 minutes. Start your free claim analysis → Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal